1. Current and emerging therapies in unresectable and recurrent gastric cancer
   Erin Jou et al, 2016, WJG CrossRef
2. Hidden Markov Model-Based CNV Detection Algorithms for Illumina Genotyping Microarrays
   Eric L. Seiser et al, 2014, Cancer Informatics CrossRef
3. Recent advances in the HER2 targeted therapy of gastric cancer
   Tasuku Matsuoka, 2015, WJCC CrossRef
4. Cooperative oncogenic effect and cell signaling crosstalk of co-occurring HER2 and mutant PIK3CA in mammary epithelial cells
   Lun Dong et al, 2017 CrossRef
5. The Notch Pathway in Breast Cancer Progression.
   Emmanuel N Kontomanolis et al, 2018, ScientificWorldJournal CrossRef
6. In Silico Evaluation of Two Targeted Chimeric Proteins Based on Bacterial Toxins for Breast Cancer Therapy
   Zoleikha Goleij et al, 2019, Int J Cancer Manag CrossRef
7. In Silico Designing a Candidate Vaccine Against Breast Cancer
   Amir Atapour et al, 2019, Int J Pept Res Ther CrossRef
8. Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2–Akt axis
   B S Vinod et al, 2015, Cell Death Discovery CrossRef
9. The Role of Pharmacogenomics in Individualized Medicine
   Henriette E. Meyer zu Schwabedissen, 2015 CrossRef
10. Relatives of Crohn's disease patients and breast cancer: an overlooked condition.
    Gianluca Pellino et al, 0 CrossRef
11. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target
    Min Joung Lee et al, 2016, J Cancer Res Clin Oncol CrossRef
12. A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients.
    Xinna Zhou et al, 2015, Springerplus CrossRef
13. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma
    Maria T. Bourlon et al, 2016, Cancer Med CrossRef
14. AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion
    Jie Zhang et al, 2019, Disease Markers CrossRef
15. In Silico Design and Evaluation of scFv-CdtB as a Novel Immunotoxin for Breast Cancer Treatment
    Asma Vafadar et al, 2020, Int J Cancer Manag CrossRef
16. Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
    Maria Gaibar et al, 2020, Journal of Oncology CrossRef
17. The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance
    Ajeya Nandi et al, 2020, Genes Dev. CrossRef
18. Feline Mammary Carcinoma: Past, Present and Future
    A. Gameiro et al, 2020 CrossRef
19. Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
    Stacy L. Moulder et al, 2017, Clin Cancer Res CrossRef
20. Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition
    Monica E. Wielgos et al, 2018, Mol Cancer Ther CrossRef
21. IL-8 secreted by tumor associated macrophages contribute to lapatinib resistance in HER2-positive locally advanced breast cancer via activation of Src/STAT3/ERK1/2-mediated EGFR signaling
    Shaza Ahmed et al, 2021, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research CrossRef
22. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion
    Sangsu Park et al, 2021, IJMS CrossRef
23. Theranostic Approach in Breast Cancer: A Treasured Tailor for Future Oncology.
    Narges Jokar et al, 2021, Clin Nucl Med CrossRef
24. Development of a Novel Anti-HER2 Monoclonal Antibody H2Mab-181 for Gastric Cancer
    Junko Takei et al, 2021, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy CrossRef
25. Predicting cancer outcomes with radiomics and artificial intelligence in radiology
    Kaustav Bera et al, 2021, Nat Rev Clin Oncol CrossRef
26. A Retrospective analysis of biosimilar and reference trastuzumab in human epidermal growth factor receptor-2 positive early and/or locally advanced breast cancer patients treated with neoadjuvant-adjuvant setting: Safety and event-free survival outcomes
    Rahul Kulkarni et al, 2021, Oncol J India CrossRef
27. Epitope Mapping of an Anti-HER2 Monoclonal Antibody (H2Mab-181) Using Enzyme-Linked Immunosorbent Assay
    Teizo Asano et al, 2021, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy CrossRef
28. Biomarkers in Breast Carcinomas
    Yasemin Sahin et al, 2022 CrossRef
29. Recent advances in nanoscale targeted therapy of HER2-positive breast cancer
    Yadollah Omidi et al, 2022, Journal of Drug Targeting CrossRef
30. Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review
    Mattia Lunardi et al, 2022, BMC Cancer CrossRef
31. Dose-Reduced Trastuzumab Emtansine: Active and Safe in Acute Hepatic Dysfunction
    Adam Sharp et al, 2015, Case Rep Oncol CrossRef
32. Resistance to Intervention: Paclitaxel in Breast Cancer.
    Vipin Mohan Dan et al, 2021, Mini Rev Med Chem CrossRef
33. Boesenbergia Pandurata as an Anti-Breast Cancer Agent: Molecular Docking and ADMET Study
    Mohammad Rizki Fadhil Pratama et al, 2022, LDDD CrossRef
34. A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer
    Moudi M. Alasmari, 2022, Cancers CrossRef
35. Acalabrutinib as a novel hope for the treatment of breast and lung cancer: an in-silico proof of concept
    Kedar Khaparkhuntikar et al, 2023, Journal of Biomolecular Structure and Dynamics CrossRef
36. Liposome-Based Drug Delivery—A New Therapeutic Paradigm
    Laukik Shetye et al, 2023 CrossRef
37. Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer
    Sandra Cotino-Nájera et al, 2023, Front. Pharmacol. CrossRef
38. Is Curcumin the Answer to Future Chemotherapy Cocktail?
    Wei-Yang Kong et al, 2021, Molecules CrossRef